Harrow Announces Commercial Launch of BYOOVIZ® in the United States
Harrow announced the U.S. commercial launch of BYOOVIZ, the first FDA-approved ophthalmology biosimilar referencing LUCENTIS, developed in partnership with Samsung Bioepis. The product enters an estimated $9 billion U.S. anti-VEGF market, leveraging exclusive commercialization rights that also cover the upcoming OPUVIZ biosimilar.
Key figures
- Market size usd
- $9 billion
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.